Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment

Pharmacoepidemiology and Drug Safety

Volumn 26, Issue 1, 2017, Pages 1-8

  Sagwa, Evans L ^a   Souverein, Patrick C ^a   Ribeiro, Inês ^b   Leufkens, Hubert G M ^a   Mantel Teeuwisse, Aukje K ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

Author keywords

disproportionality analysis; drug safety; drug resistant tuberculosis; hearing loss; pharmacoepidemiology; pharmacovigilance

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; STREPTOMYCIN; AMINOGLYCOSIDE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; DRUG SURVEILLANCE PROGRAM; FEMALE; HEARING IMPAIRMENT; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; OTOTOXICITY; PRIORITY JOURNAL; TINNITUS; VERTIGO; CHEMICALLY INDUCED; COMPARATIVE STUDY; FACTUAL DATABASE; HEARING LOSS; MIDDLE AGED; TUBERCULOSIS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AMINOGLYCOSIDES; ANTITUBERCULAR AGENTS; CAPREOMYCIN; DATABASES, FACTUAL; FEMALE; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; PHARMACOVIGILANCE; TINNITUS; TUBERCULOSIS; VERTIGO;

EID: 85006092456     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.4125     Document Type: Article

References (38)

1. Mathers C, Smith A, Concha M. Global Burden of Hearing Loss in the Year 2000. : Geneva, 2001.
2. Cianfrone G, Pentangelo D, Altissimi G, Turchetta R. Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide. Eur Rev Med Pharmacol Sci 2011; 15: 601–36.
3. Kaplan W, Wirtz. J. Veronika, Mantel-Teeuwisse AK, Stolk, P, Duthey B, Laing R. Priority Medicines for Europe and the World 2013 Update. Geneva, Switzerland: 2013.
4. Di Perri G, Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J Antimicrob Chemother 2004; 54: 593–602.
5. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621–9.
6. World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: 2008.
7. Frymark T, Leech H, Mullen R, Schooling T, Venediktov R, Wang B. Drug-Induced Hearing Loss—Aminoglycosides. Rockville: MD, 2010.
8. Selimoglu E, Kalkandelen S, Erdogan F. Comparative vestibulotoxicity of different aminoglycosides in the Guinea Pigs. Yonsei Med J 2003; 44: 517–22.
9. World Health Organization (WHO). Global Tuberculosis Report, 2014. Geneva, Switzerland: 2014.
10. World Health Organization (WHO). MDR-TB 2014 update. Geneva, Switzerland: 2014.
11. Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J 2008; 42: 409–19.
12. Uppsala Monitoring Center. Uppsala Monitoring Centre (UMC) Website [Internet]. 2015 [cited 2015 May 4];
13. Uppsala Monitoring Center. The WHO Adverse Reaction Terminology—WHO-ART [Internet]. 2014 [cited 2014 Dec 15];5.
14. ICH. Medical Dictionary for Regulatory Activities (MedDRA) [Internet]. 2015 [cited 2015 May 4];
15. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004; 13: 519–23.
16. Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16: 355–65.
17. Van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection is spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 3–10.
18. Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 2011; 72: 905–8.
19. Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol 2011; 2011: 937861.
20. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother 1989; 33: 797–800.
21. Black RE, Lau WK, Weinstein RJ, Young LS, Hewitt WL. Ototoxicity of Amikacin. Antimicrob Agents Chemother 1976; 9: 956–61.
22. Reza M, Abtahi B, Gholami K. The incidence of amikacin ototoxicity in multidrug-resistant tuberculosis patients. Iran J Pharm Res 2011; 10: 905–11.
23. Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J 2012; 40: 1277–86.
24. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord 2007; 7: 5.
25. Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HGM, Mantel-Teeuwisse AK. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. BMC Pharmacol Toxicol 2015; 16: 36.
26. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004; 38: 1538–44.
27. Palleria C, Leporini C, Chimirri S, et al. Limitations and obstacles of the spontaneous adverse drugs reactions reporting: two “challenging” case reports. J Pharmacol Pharmacother 2013; 4: S66–72.
28. Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf 2013; 36: 75–81.
29. Sturdy A, Goodman A, José RJ, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011; 66: 1815–20.
30. Raphael Y. Cochlear pathology, sensory cell death and regeneration. Br Med Bull 2002; 63: 25–38.
31. Appiah B. Africa struggles to improve drug safety. Can Med Assoc J 2012; 184: E533–4.
32. Program SPS. Safety of Medicines in Sub-Saharan Africa: Assessment of Pharmacovigilance Systems and their Performance. Virginia: Arlington, 2011.
33. Maigetter K, Pollock AM, Kadam A, Ward K, Weiss MG. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements. Int J Heal Policy Manag 2015; 4: 295–305.
34. Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries. Drug Saf 2010; 33: 689–703.
35. Walls T, Shingadia D. The epidemiology of tuberculosis in Europe. Arch Dis Child 2007; 92: 726–9.
36. Furin J, Isaakidis P, WHO, et al. The tuberculosis emergency in eastern Europe. Lancet HIV 2016; 3: e107–8.
37. Waller P, van Puijenbroek E, Egberts A, Evans S. The reporting odds ratio versus the proportional reporting ratio: “Deuce.”. Pharmacoepidemiol Drug Saf 2004; 13: 525–6.
38. De Boer A. When to publish measures of disproportionality derived from spontaneous reporting databases? Br J Clin Pharmacol 2011; 72: 909–11.